A biotech company, reportedly valued at $10 billion, is working on de-extinction efforts, including bringing back mammoths and possibly other species such as the dire wolf and an extinct antelope. The company's claims about its progress, including the revival of the dire wolf, have been met with some skepticism from scientists. The firm's work may also have potential applications beyond de-extinction, including transforming human health.